Journal of Pathology and Translational Medicine

Original Articles

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression: Young Wha Koh, Jae-Ho Han, Seong Yong Park, Dok Hyun Yoon, Cheolwon Suh, Jooryung Huh; J Pathol Transl Med. 2017;51(2):152-158. Published online February 21, 2017; DOI: https://doi.org/10.4132/jptm.2016.11.03

8,829 View
232 Download
19 Web of Science
18 Crossref

Background
Glucose transporter type 1 (GLUT1) expression is linked to glucose metabolism and tissue hypoxia. A recent study reported that GLUT1 was significantly associated with programmed death ligand 1 (PD-L1) as a therapeutic target in relapsed or refractory classical Hodgkin’s lymphoma (cHL). The purpose of this study was to measure the expression of GLUT1 and assess its prognostic significance and potential relationships with PD-L1, programmed death ligand 2 (PD-L2), and programmed death-1 (PD-1) expressions in cHL. Methods: Diagnostic tissues from 125 patients with cHL treated with doxorubicin, bleomycin, vinblastine, and dacarbazine were evaluated retrospectively via immunohistochemical analysis of GLUT1, PD-L1, PD-L2, and PD-1 expression. Results: The median follow-up time was 4.83 years (range, 0.08 to 17.33 years). GLUT1, PD-L1, PD-L2, and PD-1 were expressed in 44.8%, 63.2%, 9.6%, and 13.6% of the specimens, respectively. Positive correlations were found between GLUT1 and PD-L1 expression (p = .004) and between GLUT1 and PD-L2 expression (p = .031). GLUT1 expression in Hodgkin/Reed-Sternberg (HRS) cells was not associated with overall survival or event-free survival (EFS) in the entire cohort (p = .299 and p = .143, respectively). A subgroup analysis according to the Ann Arbor stage illustrated that GLUT1 expression in HRS cells was associated with better EFS in advanced-stage disease (p = .029). A multivariate analysis identified GLUT1 as a marginally significant prognostic factor for EFS (p = .068). Conclusions: This study suggests that GLUT1 expression is associated with better clinical outcomes in advanced-stage cHL and is significantly associated with PD-L1 and PD-L2 expressions.

Citations

Citations to this article as recorded by

Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma
Yuyang Pang, Tingxun Lu, Zijun Y. Xu-Monette, Ken H. Young
International Journal of Molecular Sciences.2023; 24(6): 5493. CrossRef
Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression
Kun Wang, Xiaoyong Dai, Albert Yu, Chunyan Feng, Kewei Liu, Laiqiang Huang
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
TIMP-1 Dependent Modulation of Metabolic Profiles Impacts Chemoresistance in NSCLC
Wei Xiao, Pankaj Ahluwalia, Lan Wang, John Howard, Ravindra Kolhe, Amyn M. Rojiani, Mumtaz V. Rojiani
Cells.2022; 11(19): 3036. CrossRef
Hypoxia-related tumor environment correlated with immune infiltration and therapeutic sensitivity in diffuse large B-cell lymphoma
Chen Liu, Lin Liu
Frontiers in Genetics.2022;[Epub] CrossRef
Non-invasive measurement of PD-L1 status and prediction of immunotherapy response using deep learning of PET/CT images
Wei Mu, Lei Jiang, Yu Shi, Ilke Tunali, Jhanelle E Gray, Evangelia Katsoulakis, Jie Tian, Robert J Gillies, Matthew B Schabath
Journal for ImmunoTherapy of Cancer.2021; 9(6): e002118. CrossRef
Tumor immunity is related to 18F‐FDG uptake in thymic epithelial tumor
Hisao Imai, Kyoichi Kaira, Kosuke Hashimoto, Hiroyuki Nitanda, Ryo Taguchi, Akitoshi Yanagihara, Tetsuya Umesaki, Ou Yamaguchi, Atsuto Mouri, Tomonori Kawasaki, Masanori Yasuda, Kunihiko Kobayashi, Hirozo Sakaguchi, Ichiei Kuji, Hiroshi Kagamu
Cancer Medicine.2021; 10(18): 6317. CrossRef
Transcutaneous Carbon Dioxide Decreases Immunosuppressive Factors in Squamous Cell Carcinoma In Vivo
Nanae Yatagai, Takumi Hasegawa, Rika Amano, Izumi Saito, Satomi Arimoto, Daisuke Takeda, Yasumasa Kakei, Masaya Akashi, Peter J. Oefner
BioMed Research International.2021; 2021: 1. CrossRef
Current Role of Functional Imaging in the Management of Lymphoma
Bruce D. Cheson, Michel Meignan
Current Oncology Reports.2021;[Epub] CrossRef
Diagnostic value of 18F-FDG-PET to predict the tumour immune status defined by tumoural PD-L1 and CD8+tumour-infiltrating lymphocytes in oral squamous cell carcinoma
Maria Togo, Takehiko Yokobori, Kimihiro Shimizu, Tadashi Handa, Kyoichi Kaira, Takaaki Sano, Mariko Tsukagoshi, Tetsuya Higuchi, Satoshi Yokoo, Ken Shirabe, Tetsunari Oyama
British Journal of Cancer.2020; 122(11): 1686. CrossRef
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape
Xianjie Jiang, Jie Wang, Xiangying Deng, Fang Xiong, Junshang Ge, Bo Xiang, Xu Wu, Jian Ma, Ming Zhou, Xiaoling Li, Yong Li, Guiyuan Li, Wei Xiong, Can Guo, Zhaoyang Zeng
Molecular Cancer.2019;[Epub] CrossRef
Fluorodeoxyglucose uptake is associated with low tumor-infiltrating lymphocyte levels in patients with small cell lung cancer
Norimitsu Kasahara, Kyoichi Kaira, Koichi Yamaguchi, Hiroaki Masubuchi, Hiroaki Tsurumaki, Kenichiro Hara, Yasuhiko Koga, Reiko Sakurai, Tetsuya Higuchi, Tadashi Handa, Tetsunari Oyama, Takehiko Yokobori, Kimihiro Shimizu, Takayuki Asao, Takeshi Hisada
Lung Cancer.2019; 134: 180. CrossRef
MYC Expression and Metabolic Redox Changes in Cancer Cells: A Synergy Able to Induce Chemoresistance
Barbara Marengo, Ombretta Garbarino, Andrea Speciale, Lorenzo Monteleone, Nicola Traverso, Cinzia Domenicotti
Oxidative Medicine and Cellular Longevity.2019; 2019: 1. CrossRef
Sustain, Adapt, and Overcome—Hypoxia Associated Changes in the Progression of Lymphatic Neoplasia
Orsolya Matolay, Gábor Méhes
Frontiers in Oncology.2019;[Epub] CrossRef
Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma
Norimitsu Kasahara, Kyoichi Kaira, Pinjie Bao, Tetsuya Higuchi, Yukiko Arisaka, Bilguun Erkhem-Ochir, Noriaki Sunaga, Yoichi Ohtaki, Toshiki Yajima, Takayuki Kosaka, Tetsunari Oyama, Takehiko Yokobori, Takayuki Asao, Masahiko Nishiyama, Yoshito Tsushima,
Lung Cancer.2018; 119: 71. CrossRef
High Serum Level of Soluble Programmed Death Ligand 1 is Associated With a Poor Prognosis in Hodgkin Lymphoma
Xiaofang Guo, Juan Wang, Jietian Jin, Hao Chen, Zijun Zhen, Wenqi Jiang, Tongyu Lin, Huiqiang Huang, Zhongjun Xia, Xiaofei Sun
Translational Oncology.2018; 11(3): 779. CrossRef
Hodgkin lymphoma and imaging in the era of anti-PD-1/PD-L1 therapy
Margarita Kirienko, Martina Sollini, Arturo Chiti
Clinical and Translational Imaging.2018; 6(6): 417. CrossRef
New developments in the pathology of malignant lymphoma: a review of the literature published from January to April 2017
J. Han van Krieken
Journal of Hematopathology.2017; 10(1): 25. CrossRef
Programmed cell death ligands expression in phaeochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior
David J. Pinato, James R. Black, Sebastian Trousil, Roberto E. Dina, Pritesh Trivedi, Francesco A. Mauri, Rohini Sharma
OncoImmunology.2017; 6(11): e1358332. CrossRef

Differential Expression of Glut1 in Pulmonary Neuroendocrine Tumors: Correlation with Histological Grade.: Hyun Ju Lee, Seol Bong Yoo, Won Woo Lee, Doo Hyun Chung, Jeong Wook Seo, Jin Haeng Chung; Korean J Pathol. 2009;43(3):201-205.; DOI: https://doi.org/10.4132/KoreanJPathol.2009.43.3.201

3,668 View
31 Download
2 Crossref

Abstract PDF

BACKGROUND
Increased glucose uptake, a process that is mediated by glucose transporter (Glut1) proteins, is an important metabolic feature in a variety of cancer cells. The overexpression of Glut1 in human cancers is known to be related to a variety of histopathological parameters, including histological grade, proliferation rate, and lymphatic invasion. The principal objective of this study was to evaluate Glut1 expression in the spectrum of pulmonary neuroendocrine (NE) tumors including typical carcinoid tumor (TC), atypical carcinoid tumor (AC), large cell neuroendocrine carcinoma (LCNEC), and small cell carcinoma (SCC), and to characterize the relationship between Glut1 expression and the histologic grade of NE tumors.
METHODS
19 TC, 7 AC, 13 LCNEC, and 6 SCC patients were included in this study. The percentages of Glut1-positive tumor cells in these patients were determined. For statistical analysis, Glut1 expression was subdivided into a Glut1-low expression group (0-30%) and a Glut1-high expression group (31-90%).
RESULTS
In our subgroup analyses, the histological grade of pulmonary neuroendocrine (NE) tumors was significantly correlated with Glut1 expression; TC (n=19, 3.6+/-4.2%), AC (n=7, 20.0+/-4.9%), LCNEC (n=13, 60.0+/-21.1%), and SCC (n=6, 74.2+/-16.9%). Glut1-high expression was significantly associated with high-grade NE tumors such as LCNEC and SCC (n=19, 62.6+/-21.0%) (p=0.000).
CONCLUSIONS
The results of this study appear to indicate that Glut1 overexpression is a consistent feature of high-grade NE lung tumors.

Citations

Citations to this article as recorded by

GLUT1: A novel tool reflecting proliferative activity of lung neuroendocrine tumors?
Nazim Benzerdjeb, Pascal Berna, Henri Sevestre
Pathology International.2017; 67(1): 32. CrossRef
Oncocytic carcinoid tumor of the lung with intense F-18 fluorodeoxyglucose (FDG) uptake in positron emission tomography–computed tomography (PET/CT)
Yuki Tanabe, Yoshifumi Sugawara, Rieko Nishimura, Kohei Hosokawa, Makoto Kajihara, Teruhiko Shimizu, Tadaaki Takahashi, Shinya Sakai, Shigeki Sawada, Motohiro Yamashita, Haruhiko Ohtani
Annals of Nuclear Medicine.2013; 27(8): 781. CrossRef

First
Prev
Page of 1
Next
Last

Search